PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Site Search
Dr. Skach discusses the latest advances in CF research and exciting new approaches to address the underlying cause of the disease.
Positivity and the opportunity to be around for the “long haul” are what motivate Dana Curry to do her daily treatments. Hear Dana's top tips for staying on top of her CF treatment plan.
When I was diagnosed with CF at 22, I was relieved. I could start treating the disease we'd been trying to identify for years. But after the initial excitement, I started facing issues of denial, anger and confusion…so I ran.
For most of my 30 years, my life has been on the same path as my peers'. But suddenly, things feel different.
In the third plenary of NACFC, three guidelines authors announced the publication of guidelines for screening and treating depression and anxiety, and explained how the guidelines were developed. Read on for my thoughts.
Hear from John P. Clancy, M.D., the first plenary speaker at this year's NACFC, about recent advances in personalized medicine, which could allow clinicians to better tailor treatment to the individual with CF.
The time has come to redefine success and what it should look like in the CF community.
Matt James, an adult with CF, and Anna Georgiopoulos, M.D., discuss the importance of mental health in CF care, including what to expect from the recently published guidelines for screening and treating depression and anxiety. Watch the One-on-One Live video here.
The Foundation hosted a small conference that brought together CF scientists, clinical researchers, and biotechnology and pharmaceutical industry representatives. Learn more and watch a short video of attendees sharing their thoughts about the progress we are making in CF research.